PomDoctor raised $20 million, below new Nasdaq minimum of $25 million. IPO priced at lower end, valuing PomDoctor at $472 million. Company's high P/S ratio of 10 appears aggressive for current growth. PomDoctor faces potential listing and financial challenges ahead. Rising shares show initial investor interest, yet financial risks loom.
PomDoc plans a Nasdaq listing to raise $30 million. Company faces significant financial challenges with high liabilities. Market capitalization targets appear aggressive compared to profitable competitors. Focus on chronic disease management may provide a niche market advantage. IPO success is uncertain due to shaky financial position and auditor concerns.